Key facts
- Optimi Health has completed commercial psilocybin production.
- The company aims to treat treatment-resistant depression in Australia.
- Optimi Health focuses on developing and supplying psychedelic-assisted therapies.
Optimi Health has announced the successful completion of its commercial psilocybin production. This milestone is a significant step towards addressing the growing need for treatments for conditions like treatment-resistant depression in Australia. The company's focus is on the development and supply of psychedelic-assisted therapies, positioning itself within the emerging field of mental health innovation.